Correlation Between Franklin Genomic and TrueShares Technology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Franklin Genomic and TrueShares Technology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Franklin Genomic and TrueShares Technology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Franklin Genomic Advancements and TrueShares Technology AI, you can compare the effects of market volatilities on Franklin Genomic and TrueShares Technology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Franklin Genomic with a short position of TrueShares Technology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Franklin Genomic and TrueShares Technology.

Diversification Opportunities for Franklin Genomic and TrueShares Technology

-0.56
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Franklin and TrueShares is -0.56. Overlapping area represents the amount of risk that can be diversified away by holding Franklin Genomic Advancements and TrueShares Technology AI in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on TrueShares Technology and Franklin Genomic is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Franklin Genomic Advancements are associated (or correlated) with TrueShares Technology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of TrueShares Technology has no effect on the direction of Franklin Genomic i.e., Franklin Genomic and TrueShares Technology go up and down completely randomly.

Pair Corralation between Franklin Genomic and TrueShares Technology

Given the investment horizon of 90 days Franklin Genomic is expected to generate 15.6 times less return on investment than TrueShares Technology. But when comparing it to its historical volatility, Franklin Genomic Advancements is 1.62 times less risky than TrueShares Technology. It trades about 0.01 of its potential returns per unit of risk. TrueShares Technology AI is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  2,368  in TrueShares Technology AI on August 30, 2024 and sell it today you would earn a total of  1,854  from holding TrueShares Technology AI or generate 78.29% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Franklin Genomic Advancements  vs.  TrueShares Technology AI

 Performance 
       Timeline  
Franklin Genomic Adv 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Franklin Genomic Advancements has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Etf's essential indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the ETF investors.
TrueShares Technology 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in TrueShares Technology AI are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, TrueShares Technology showed solid returns over the last few months and may actually be approaching a breakup point.

Franklin Genomic and TrueShares Technology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Franklin Genomic and TrueShares Technology

The main advantage of trading using opposite Franklin Genomic and TrueShares Technology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Franklin Genomic position performs unexpectedly, TrueShares Technology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TrueShares Technology will offset losses from the drop in TrueShares Technology's long position.
The idea behind Franklin Genomic Advancements and TrueShares Technology AI pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Complementary Tools

FinTech Suite
Use AI to screen and filter profitable investment opportunities
Money Managers
Screen money managers from public funds and ETFs managed around the world
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Transaction History
View history of all your transactions and understand their impact on performance
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes